Maryland-based biotechnology leader, Elixirgen Scientific, Inc., launches Alzheimer’s Disease Panel, strengthening their commitment to quality and innovation in disease research and drug discovery.

Baltimore-based biotechnology leader, Elixirgen Scientific, Inc., achieves ISO 9001:2015 Quality Management System certification, strengthening commitment to quality, excellence in biotechnology and drug discovery.

A new research team at the BioMed X Institute will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease.

Powered by Sanofi, a new BioMed X research team will develop a computational platform designed to accelerate drug development.

Next-generation proteomics technology made available to the biotech and pharmaceutical industry through the acquisition of Methuselah Health by leading R&D services provider, RxCelerate

At the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences' proprietary PhAROS drug discovery platform.

Seattle-based primary cell biology CRO ReachBio and Swiss biotech abc biopply announced today a partnership to jointly co-market their preclinical test models. The two companies plan to support their clients with an even more predictive assay portfolio to further increase the efficiency of their drug discovery and development process.

World-first as adaptive chemical space is launched as a service

Free, Virtual Symposium, April 25-26, 2022

Charles River will license Hera's SRG rat (OncoRat), the first highly immunocompromised rat model

New digital pathology, quantitative image analysis and quantitative AI method for liver tissues is presented for the continuous assessment of the histological phenotype(s) of fibrosis, including severity and regression of fibrosis in Human in-vitro 3D NASH Spheroid models, NASH rodent models, Clinical Phase2b NASH Studies at the Liver Meeting Digital Experience™ 2021

In the face of unprecedented workplace changes, senior HR leader will continue the evolution of BenchSci's progressive and award-winning culture

Addition of new product type to the BenchSci platform empowers scientists with relevant experimental evidence to accelerate novel medicine to clinical trials

Industry veteran will provide strategic guidance to company as it pursues its vision of using machine learning to bring novel medicine to patients 50% faster by 2025

Experienced product and engineering leader Eran Ben-Ari joins BenchSci to scale the creation of a sophisticated machine learning-based product portfolio that's transforming life-saving R&D

Steve Hitchcock, Philip Larsen, and Philip Tagari named science advisors, providing BenchSci with global industry expertise to realize its vision of using machine learning to bring novel medicine to patients 50% faster by 2025

11 Billion Novel Molecules: CHEMriya - OTAVA's On-Demand Chemical Space

3Brain AG has announced a new technology based on a unique combination of microchips and AI that promises to change the way drug candidates are selected at the preclinical level to enter into clinical trials - and to maximize their chances of success.

There is free registration for all interested attendees: http://tinyurl.com/SDDS2021.
Co-Sponsored by the Stanford Cardiovascular Institute, Stanford Cancer Institute, Stanford Cardiovascular Health, and many others.

Recognition reflects vision to bring medicine to patients 50% faster by 2025, reaffirms dedication to employee wellbeing

The Manke Lab at UMass Dartmouth is a global leader in novel tryptamine synthesis and characterization

The collaborative research aims to fill several gaps in the scientific understanding of the chemical composition of psychedelic psilocybin-containing mushrooms

Agreement will enhance BenchSci's vast biomedical database to help scientists run more successful experiments while increasing discoverability of Taylor & Francis Group research

Some of the major precision Medicine market players are Tepnel Pharma Services, Biocrates Life Sciences, Qiagen, Novartis, NanoString Technologies, Menarini Silicon Biosystems, Pfizer, Eagle Genomics, Roche, Intomics, Quest Diagnostics, and Teva Pharmaceutical.

Industry Boosted by Reduction of Animal Research

The North American precision medicine market value surpassed USD 21 billion in 2018 and is set to achieve 9%+ CAGR from 2019 to 2025, on account of favorable government scenario coupled with increased funding for research in precision medicine.

Targeted Protein Degradation Seeing Renewed Optimism in Research Field

The Hospital workflow segment of healthcare artificial intelligence market will witness 40.6% CAGR from 2019 to 2025

Better target validation is a key driver of better productivity in drug discovery. The RNA-guided nucleases, exemplified by Cas9, represent a powerful new approach to understanding gene function and, in principle, to reveal the next generation of therapeutic targets. But how well does this technology work in practice?

Initial excitement associated with the completion of genome-scale CRISPR screens can quickly turn to dismay as the realization of the sheer quantity of data generated becomes apparent.